HYPR Hyperfine
- 0.845
- +0.014+1.68%
Hyperfine News
Hyperfine Announced The Acceptance Of Seventeen Ultra-low-field MRI-related Abstracts To Be Presented At The 2024 International Society For Magnetic Resonance In Medicine Annual Meeting In Singapore
Hyperfine Announced The Acceptance Of Seventeen Ultra-low-field MRI-related Abstracts To Be Presented At The 2024 International Society For Magnetic Resonance In Medicine Annual Meeting In Singapore
Hyperfine, Inc. Takes the Stage at ISMRM With Seventeen Abstracts Assessing the Potential of Using Swoop System Images Across Multiple Care Settings and Clinical Conditions
Data on the company's portable MR imaging system show it can acquire brain images at the point of care that may assist physicians with screening and monitoring for Alzheimer's and multiple sclerosis b
Express News | Leading Institutions Enroll First Alzheimer’s Patients Receiving Amyloid-Targeting Therapy in Care Pmr Study
Leading Institutions Enroll First Alzheimer's Patients Receiving Amyloid-Targeting Therapy in CARE PMR Study
Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology company that has redefined brain imaging with the first FDA-cleared portable magnetic resonance (MR) brain imaging system—the Swoop system—today announced that the first patients have been enrolled in the CARE PMR (Capturing ARIA Risk Equitably with Portable MR) observational study.
SEC Baby Shelf Rules Stunt Hyperfine Inc.'s Fundraising Flexibility
Hyperfine Price Target Cut to $1.60/Share From $2.10 by Wells Fargo
Hyperfine Price Target Cut to $1.60/Share From $2.10 by Wells Fargo
Hyperfine Is Maintained at Equal-Weight by Wells Fargo
Hyperfine Is Maintained at Equal-Weight by Wells Fargo
Hyperfine Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 03/22/2024 60.8% Wells Fargo $2.1 → $1.6 Maintains Equal-Weight 11/30/2023 25.63% Jefferies → $1.25 Initia
Canopy Growth, Capricor Therapeutics, GT Biopharma Among Healthcare Movers
Q4 2023 Hyperfine Inc Earnings Call
B. Riley Trims Hyperfine's PT to $1.30 From $1.70 After 'Disappointing' Q4 2023 Sales, 2024 Guidance; Maintains Buy Rating
B. Riley Trims Hyperfine's PT to $1.30 From $1.70 After 'Disappointing' Q4 2023 Sales, 2024 Guidance; Maintains Buy Rating.
Challenges Ahead: Revising Hyperfine's Outlook Amid Lower-than-Expected Financial Performance
Earnings Call Summary | Hyperfine(HYPR.US) Q4 2023 Earnings Conference
The following is a summary of the Hyperfine, Inc. (HYPR) Q4 2023 Earnings Call Transcript:Financial Performance:Hyperfine reported Q4 revenue of $2.7 million, an impressive 89% increase from the previ
12 Health Care Stocks Moving In Thursday's After-Market Session
GainersBiolase (NASDAQ:BIOL) stock rose 20.0% to $0.18 during Thursday's after-market session. The market value of their outstanding shares is at $3.4 million. As per the press release, Q4 earnings ca
Recap: Hyperfine Q4 Earnings
Hyperfine (NASDAQ:HYPR) reported its Q4 earnings results on Thursday, March 21, 2024 at 04:05 PM.Here's what investors need to know about the announcement.EarningsHyperfine beat estimated earnings by
Hyperfine Q4 EPS $(0.15) Beats $(0.18) Estimate, Sales $2.69M Miss $3.71M Estimate
Hyperfine (NASDAQ:HYPR) reported quarterly losses of $(0.15) per share which beat the analyst consensus estimate of $(0.18) by 16.67 percent. This is a 21.05 percent increase over losses of $(0.19) pe
Hyperfine 4Q Loss/Shr 15c >HYPR
Hyperfine 4Q Loss/Shr 15c >HYPR
Hyperfine 4Q Sales $2.69M >HYPR
Hyperfine 4Q Sales $2.69M >HYPR
Earnings Flash (HYPR) HYPERFINE Posts Q4 Revenue $2.7M
04:06 PM EDT, 03/21/2024 (MT Newswires) -- Earnings Flash (HYPR) HYPERFINE Posts Q4 Revenue $2.7M
Press Release: Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results
Hyperfine, Inc. Reports Fourth Quarter and Full Year 2023 Financial Results GUILFORD, Conn., March 21, 2024 (GLOBE NEWSWIRE) -- Hyperfine, Inc. (Nasdaq: HYPR), the groundbreaking health technology co
Analysis
Price Target
No Data
